Last update 07 Nov 2024

Adalimumab biosimilar (Biocon)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Adalimumab Biosimilar (Biocon Ltd.), アダリムマブ, アダリムマブ(遺伝子組換え)
+ [8]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Enthesitis-Related Arthritis
AU
14 May 2021
Hidradenitis Suppurativa
AU
14 May 2021
Ankylosing Spondylitis
JP
29 Jun 2020
Arthritis, Psoriatic
JP
29 Jun 2020
Behcet's uveitis
JP
29 Jun 2020
Colitis, Ulcerative
JP
29 Jun 2020
Crohn Disease
JP
29 Jun 2020
Panuveitis
JP
29 Jun 2020
Polyarticular Juvenile Idiopathic Arthritis
JP
29 Jun 2020
Pustular psoriasis
JP
29 Jun 2020
Rheumatoid Arthritis
JP
29 Jun 2020
Uveitis, Intermediate
JP
29 Jun 2020
Uveitis, Posterior
JP
29 Jun 2020
Juvenile Idiopathic Arthritis
EU
17 Sep 2018
Juvenile Idiopathic Arthritis
IS
17 Sep 2018
Juvenile Idiopathic Arthritis
LI
17 Sep 2018
Juvenile Idiopathic Arthritis
NO
17 Sep 2018
Pediatric Crohn's Disease
EU
17 Sep 2018
Pediatric Crohn's Disease
IS
17 Sep 2018
Pediatric Crohn's Disease
LI
17 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
374
(Group 1 :- Humira Continuously)
nnjkqyterr(xieilcywta) = lszetannam otxtodfrto (opwlfzwnce, zigalwgcbt - euyocmqvkv)
-
15 Oct 2024
(Group 2:- Repeated Switches Humira - Hulio)
nnjkqyterr(xieilcywta) = roxhxyojfd otxtodfrto (opwlfzwnce, fonyrrsgxr - gnwjssjrfm)
Phase 3
730
Methotrexate+Adalimumab-FKB-327
prgbkffsuo(kbaiwqgdwq) = omsjzmauke nwaypehtcb (stpcdylllo )
Similar
12 Dec 2019
Methotrexate+adalimumab
prgbkffsuo(kbaiwqgdwq) = totuyyaycd nwaypehtcb (stpcdylllo )
Phase 3
728
kxifybqhsk(dnmntldwau) = dmrmnqnvuc qhjeazhhpl (ebsrpzxydn, 77.1 - 88.3)
Positive
12 Jun 2019
Adalimumab RP
kxifybqhsk(dnmntldwau) = xevystjvic qhjeazhhpl (ebsrpzxydn, 74.8 - 90.4)
Phase 3
728
(FKB327)
dydvtnyrjw(vlbkfbzynk) = vsyratzsnt dhetlwsuqp (qgmxyrkbcf, odbewtrggx - guxaecgfdm)
-
20 Sep 2017
(Humira®)
dydvtnyrjw(vlbkfbzynk) = gfrrhhkodr dhetlwsuqp (qgmxyrkbcf, mwlkuwxfxq - ckrdbyrsfd)
Phase 3
Rheumatoid Arthritis
C-reactive protein | antidrug antibodies
730
ftscrbczdy(rfkkiasoxy) = duooaphjxn rxccwqxhxk (fultrtxrvz )
Positive
14 Jun 2017
ADL
ftscrbczdy(rfkkiasoxy) = tgujbvndat rxccwqxhxk (fultrtxrvz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free